Loading... (0%)

3-V Biosciences to Present Clinical and Preclinical Data for FASN Inhibitors at EORTC-NCI-AACR 2014

02 October 2014

Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, will present clinical data for its lead therapeutic compound, TVB-2640, in a late-breaking oral session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 18 – 21,…

3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB- 2640 in Patients with Advanced Solid Tumors First

04 December 2013

FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the recent initiation of a Phase 1 clinical study of TVB-2640 in patients with advanced solid tumors. TVB-2640 is an oral, proprietary fatty…

3-V Biosciences Names Dr. William McCulloch Chief Medical Officer

21 November 2013

Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical Officer. Dr. McCulloch brings nearly three decades of senior research and development experience to…

3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

23 October 2013

3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pathways resulting in death of tumor cells or virally-infected cells, today presented positive data from preclinical studies of the company’s novel…

3-V Biosciences Completes $20 Million Series C Financing

21 June 2013

Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V’s lead oncology candidate into a Phase 1 clinical trial…

3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012

12 November 2012

Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of…

3­‐V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012

01 October 2012

Menlo Park, California, October 1, 2012. 3­‐V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9‐13 in Boston, Massachusetts. 3‐V Biosciences is discovering and developing oral antiviral therapeutics designed to…

3-V Biosciences Closes Preferred Stock Financing and Designates Novel Host-Factor Hepatitis C Program

09 July 2012

Menlo Park, California, January 5, 2012. 3-V Biosciences, Inc. announced today both the closing of a Preferred Stock financing and the designation of a novel program targeting a host-factor for the treatment of Hepatitis C virus (HCV). “The continued support of the company’s investors for the host-factor vision reflects both the success of the team thus…

3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology

29 June 2012

Menlo Park, California, June 29, 2012. 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology.  Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. “With our…